Dr. Umar

WEA improved PCOS in rats by restoring ovarian signaling pathways and remodeling gut microbiota, increasing taxa such as Bifidobacterium animalis and Lactobacillus murinus. These findings highlight microbiome-mediated mechanisms linking botanical therapy to metabolic and reproductive improvements.

Omega-3 PUFAs gut microbiota PCOS interactions were tested in DHEA-induced mice, revealing both microbial and direct ovarian anti-inflammatory effects that improved metabolic and reproductive dysfunction.

Quinoa improved hormonal, metabolic, ovarian, and gut microbial disturbances in a PCOS rat model by restoring PI3K/AKT/mTOR signaling, reducing excess autophagy, and correcting dysbiosis.

Metformin altered plasma microbial EVs in PCOS-IR, increasing diversity and elevating Streptococcus salivarius EVs, suggesting microbiome-mediated metabolic benefits.

A high-fat, high-fructose diet exerted stronger effects on gut microbiota than letrozole-induced PCOS in prepubertal mice, reducing SCFAs, increasing LPS, and altering key genera linked to lipid metabolism and PCOS-related metabolic disruption.

BL21 improved metabolic, hormonal, inflammatory, and microbiome dysfunction in a DHT-induced PCOS model, restoring beneficial taxa and supporting gut–brain–ovary axis regulation.

This study compared gut microbiota in Japanese women with and without PMS, identifying higher diversity and increased Collinsella, Bifidobacterium, and Blautia in PMS, suggesting microbial signatures relevant to symptom development.

This study examined gut microbiota differences in women with premenstrual symptoms, identifying decreases in key butyrate-producing and GABA-modulating bacteria linked to symptom severity, suggesting mechanistic microbiome pathways relevant to PMDs.

This study integrates fungal and bacterial sequencing to define pathogen-specific microbiome signatures in vulvovaginal candidiasis, revealing distinct CSTs shaped by C. albicans or C. glabrata and their associated bacterial communities.

This study examined vaginal microbiome signatures in women with secondary infertility, identifying Lactobacillus depletion and anaerobic enrichment, with limited microbiome response to IVF-related hormonal induction.

This study links vaginal microbiota composition—especially Lactobacillus iners dominance and Pseudomonadaceae enrichment—to IVF outcomes in women with PCOS or tubal infertility, highlighting microbial markers that may predict implantation success.

This study links estrogen levels to oral microbiome composition, inflammation, and viral load in COVID-19, identifying microbial signatures across hormonal groups that highlight estrogen’s protective role in maintaining oral microbial balance.

This study links altered vaginal microbiota—especially shifts in Lactobacillus species—to hormonal disruption in primary ovarian failure, revealing microbial signatures that correlate with reproductive hormone levels and resemble menopausal microbiome patterns.

This study examined how the premature ovarian insufficiency vaginal microbiome differs from healthy controls, identifying key microbial shifts linked to hormone disruption and ovarian dysfunction.

This study examined the vaginal microbiome in premature ovarian insufficiency, identifying reduced Lactobacillus, increased dysbiosis-associated taxa, and strong hormone–microbe correlations that suggest a microbiome–ovary interaction.

This study links menopausal syndrome with gut microbiome dysbiosis, identifying species correlated with estradiol and enriched metabolic pathways that may influence symptom severity and cardiometabolic risk.

GWUAP modulates gut microbiota and metabolites in a dysmenorrhea rat model, restoring Lactobacillus, reducing Romboutsia, correcting hormone-related metabolic pathways, and improving inflammatory and pain outcomes.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study identifies distinct ovarian microbiome differences between cancerous and noncancerous tissues, showing altered taxa and enriched pathogenic and oxidative stress–tolerant functions in ovarian cancer.

Functional gastrointestinal disorders are symptom-based gut–brain interaction syndromes with no structural lesion, involving motility, visceral sensitivity, immune activation, dysbiosis, and central processing, diagnosed using Rome IV criteria.

This study characterizes gut microbial dysbiosis in Indian children with autism, identifying Lactobacillus as a cross-population microbial signature and highlighting reduced SCFA-producers linked to neuroimmune pathways.

This study analyzes gut microbiota in children with ASD, identifying distinct microbial, functional, and disease-association patterns that highlight potential mechanisms linking microbial imbalance to ASD pathophysiology.

High-resolution microbial and genome-level signatures were used to build a fecal microbial marker panel for autism diagnosis, revealing distinct taxa, strong classifier performance, and correlations with ASD symptom severity.

Altered gut microbiota in Parkinson’s disease was examined using 16S rRNA sequencing to determine how microbial composition differs among patients, their healthy spouses, and unrelated healthy controls. The study analyzed 200 individuals and evaluated microbial diversity, specific bacterial taxa, and associations with clinical severity measured by Hoehn & Yahr staging and disease […]